Printer Friendly

Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation.

CARLSBAD, Calif., March 22 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the American College of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.
 Sunday, March 25, 2007

 Session: 1206: Vascular Disease, Hypertension and Prevention --
 V-cast Poster

 Track: ACC.Vascular Disease, Hypertension, and Prevention

 Room: Hall H

 Presentation: 1206-278

 Abstract: Statin-Like, Dose-Dependent Reductions in LDL-C and
 Apolipoprotein B With ISIS 301012, an Antisense
 Inhibitor of Apolipoprotein B, in Subjects With
 Polygenic Hypercholesterolemia

 Monday, March 26, 2007

 Session: 603: Common Challenges in Preventive Cardiology
 (7:00 - 8:30 a.m. CT)

 Track: ACC.Symposium

 Room: Auditorium B

 Presentation: 603-8

 Time: 8:15 - 8:30 a.m.

 Speaker: Dr. Evan A. Stein

 Title: High Low-Density Lipoprotein Cholesterol on Three Drugs*
 *to include preliminary results of an ongoing study
 evaluating ISIS 301012 in HoFH patients on concurrent
 maximally tolerated lipid-lowering therapies

 Session: 820: Clinical Trials of Lipid-Lowering Therapy
 (4:00 - 5:30 p.m. CT)

 Track: ACC.Vascular Disease, Hypertension, and Prevention

 Room: Auditorium B

 Presentation: 820-6

 Time: 4:45 - 5:00 p.m.

 Speaker: Dr. John J.P. Kastelein

 Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B,
 Produces Significant Additional Reduction of Low-Density
 Lipoprotein Cholesterol and Apolipoprotein B in
 Hypercholesterolemic Subjects on Statins Not Meeting

 Tuesday, March 27, 2007

 Presentation: Isis Pharmaceuticals' Live Analyst/Investor Webcast

 Time: 7:00 a.m. CT


 How: Live over the Internet -- select the link on Isis' home
 page at the address above.

If you are unable to participate during the live webcast, the presentation will be available for replay at


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of ISIS 301012 in treating high cholesterol and cardiovascular disease. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, which is on file with the SEC. Copies of this and other documents are available from the Company.

CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development of Isis Pharmaceuticals, +1- -760-603-2331

Web site:
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 2007
Previous Article:Language Access Network Announces Completion of First Installation of Martti(TM) in Indian River Medical Hospital in Florida.
Next Article:IAO, PGTI and OO Update the Investment Community in All-New Interviews With

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters